Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
MRSA pneumonia
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "MRSA pneumonia" in MCE Product Catalog:
4
4 Cited Publications
Cat. No.: HY-N2187
CAS No.: 43043-74-9
3
3 Cited Publications
Synonyms: Ro 63-9141; BAL 9141
Target:
Research Areas:
Ceftobiprole (Ro 63-9141) is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci with a MIC90 value of 2 μg/mL for MRSA. Ceftobiprole also inhibits gram-positive and gram-negative pathogens. Ceftobiprole can be used for the study of hospital-acquired pneumonia (excluding ventilator-associated pneumonia) and community-acquired pneumonia .
2
2 Cited Publications
Synonyms: TAK-599 hydrate; PPI0903 hydrate
Target:
Research Areas:
Ceftaroline fosamil hydrate is a potent cephalosporin antibiotic. Ceftaroline fosamil hydrateshows broad-spectrum activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Streptococcus pneumoniae, and common Gram-negative organisms. Ceftaroline fosamil hydrate has anti-infective activity, and can be used for the research of complicated skin and skin structure infections (cSSSIs) and community-acquired bacterial pneumonia (CABP) .
1
1 Cited Publications
Cat. No.: HY-N0241
CAS No.: 85571-15-9
Cat. No.: HY-16764
CAS No.: 878592-87-1
Synonyms: JNJ-Q2
Target:
Research Areas:
Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial agent being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia with oral activity. Avarofloxacin (JNJ-Q2) is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC90 value. Avarofloxacin (JNJ-Q2) has potential for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections .
Target:
Research Areas:
Cat. No.: HY-N2245
CAS No.: 98619-25-1
Category:
Monophenols Lignans Phenols Phenylpropanoids Plants Schisandraceae Extract Disease Research Fields Schisandra chinensis (Turcz.) Baill. Cancer
Target:
Cat. No.: HY-W015464
CAS No.: 16284-60-9
Cat. No.: HY-163984
CAS No.: 2899202-97-0
Antibacterial agent 240 (compound 62-7c) is an antibacterial agent that can target multidrug-resistant (MDR) MRSA strains. Antibacterial agent 240 showed high biosafety and potent anti-infection activity in mouse pneumonia and mouse wound models of MRSA infection .
Cat. No.: HY-162761
Research Areas:
COX-1/2-IN-9 (Compound 3n) is a potent and selective inhibitor of COX-1/2, with IC50 values of 0.031 µM and 0.01 µM, respectively. COX-1/2-IN-9 possesses both antibacterial and anti-inflammatory activities, effectively inhibiting MRSA 1478 (MIC=50 μg/mL) and multidrug-resistant S. lentus (MIC=50 μg/mL). COX-1/2-IN-9 holds significant potential to alleviate MRSA-induced pneumonia in immunocompromised states .
Cat. No.: HY-16764A
CAS No.: 1001162-01-1
Synonyms: JNJ-Q2 hydrochloride
Target:
Research Areas:
Acorafloxacin hydrochloride (JNJ-Q2 hydrochloride) is a broad-spectrum fluoroquinolone anti-bacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia . Acorafloxacin hydrochloride is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC90 value . Acorafloxacin hydrochloride has potential for study of methicillin-resistant Staphylococcus aureus (MRSA) infections .
Cat. No.: HY-163615
CAS No.: 3038153-33-9
Antimicrobial agent-32 (Compound 4g) is an antimicrobial agent that exhibits significant activity against various bacteria, including Staphylococcus aureus, Bacillus subtilis, Bacillus cereus (MIC=1000 µg/mL), Klebsiella pneumonia, and Staphylococcus aureus (MRSA) (MIC=500 µg/mL), as well as Escherichia coli (MIC=250 µg/mL). Additionally, Antimicrobial agent-32 inhibits the proliferation of MCF-7, HCT-116, and HepG-2 cells, demonstrating anticancer activity .
Cat. No.: HY-W015464S1
CAS No.: 1219795-09-1
Cat. No.: HY-113718
CAS No.: 1037366-37-2
Target:
Research Areas:
DS21412020 is a fluoroquinolone antibacterial agent. DS21412020 inhibits bacterial DNA gyrase (GyrA) and topoisomerase IV, leading to DNA breaks. DS21412020 exhibits significant activity against Gram-positive bacteria such as Staphylococcus aureus (MIC = 0.006 μg/mL), Streptococcus pneumoniae (MIC = 0.05 μg/mL), and Methicillin (HY-121544)-resistant Staphylococcus aureus (MIC = 0.2 μg/mL), and Gram-negative bacteria such as Escherichia coli (MIC = 0.006 μg/mL) and Pseudomonas aeruginosa (MIC = 0.78 μg/mL). DS21412020 significantly reduces bacterial load in mouse pneumonia and MRSA infection models. DS21412020 can be used in the development of next-generation quinolone antibiotics .
Cat. No.: HY-W015464R
CAS No.: 16284-60-9
Cat. No.: HY-189648
CAS No.: 313495-77-1
Target:
Research Areas:
Antimicrobial agent-61 is an Antimicrobial agent. Antimicrobial agent-61 induces bacterial membrane depolarization and inhibits ATP synthesis. Antimicrobial agent-61 reduces bacterial burden and infection-related pathological damage in mouse models of MRSA pneumonia and MRSA keratitis. Antimicrobial agent-61 can be used for research on MRSA pneumonia and MRSA keratitis .
Cat. No.: HY-179719
Target:
Research Areas:
Anti-MRSA agent 41 (Compound 3d) is a prodrug of Mupirocin (HY-B0958), being a cholesterol disulfide conjugate of Mupirocin. Anti-MRSA agent 41 shows no antibacterial activity or cytotoxicity in vitro. Anti-MRSA agent 41 demonstrates strong anti-MRSA infection efficacy in systemic bacteremia and pneumonia mouse models. Anti-MRSA agent 41 can be used in antibiotic resistance research .
Cat. No.: HY-17626A
CAS No.: 948895-94-1
Synonyms: WCK-2349 mesylate
Target:
Research Areas:
Alalevonadifloxacin (WCK-2349) mesylate is an orally active antibiotic targeting Gram-positive and Gram-negative bacteria. Alalevonadifloxacin mesylate is promising for research of acute bacterial skin and skin structure infections and hospital-acquired pneumonia caused by MRSA and other pathogens .
Cat. No.: HY-182022
CAS No.: 3083425-49-1
Research Areas:
ZLWH-67 is a β-Carboline derivative and Antibacterial agent. ZLWH-67 inhibits DNA synthesis, suppresses biofilm formation, and increases reactive oxygen species (ROS) levels. ZLWH-67 exhibits potent in vitro antibacterial activity against MRSA (MIC = 0.5-4 μg/mL), S. epidermidis (MIC = 4 μg/mL), E. faecalis (MIC = 4-8 μg/mL), and S. pneumoniae (MIC = 16 μg/mL). ZLWH-67 displays anti-MRSA effects in murine skin and pneumonia infection models .
Cat. No.: HY-W015464S
CAS No.: 1330037-21-2
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
